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Abstract
Background: The mammalian DNA-damage response (DDR) has evolved to protect genome stability and
maximize cell survival following DNA-damage. One of the key regulators of the DDR is p53, itself tightly regulated
by MDM2. Following double-strand DNA breaks (DSBs), mediators including ATM are recruited to the site of
DNA-damage. Subsequent phosphorylation of p53 by ATM and ATM-induced CHK2 results in p53 stabilization,
ultimately intensifying transcription of p53-responsive genes involved in DNA repair, cell-cycle checkpoint control
and apoptosis.
Methods: In the current study, we investigated the stabilization and activation of p53 and associated DDR proteins
in response to treatment of human colorectal cancer cells (HCT116
p53+/+) with the MDM2 antagonist, Nutlin-3.
Results: Using immunoblotting, Nutlin-3 was observed to stabilize p53, and activate p53 target proteins.
Unexpectedly, Nutlin-3 also mediated phosphorylation of p53 at key DNA-damage-specific serine residues
(Ser15, 20 and 37). Furthermore, Nutlin-3 induced activation of CHK2 and ATM - proteins required for
DNA-damage-dependent phosphorylation and activation of p53, and the phosphorylation of BRCA1 and H2AX -
proteins known to be activated specifically in response to DNA damage. Indeed, using immunofluorescent labeling,
Nutlin-3 was seen to induce formation of gH2AX foci, an early hallmark of the DDR. Moreover, Nutlin-3 induced
phosphorylation of key DDR proteins, initiated cell cycle arrest and led to formation of gH2AX foci in cells lacking
p53, whilst gH2AX foci were also noted in MDM2-deficient cells.
Conclusion: To our knowledge, this is the first solid evidence showing a secondary role for Nutlin-3 as a DDR
triggering agent, independent of p53 status, and unrelated to its role as an MDM2 antagonist.
Background
The p53 tumour suppressor protein, often referred to as
the ‘guardian of the genom’, plays a critical role in med-
iating cellular stress responses such as that brought about
by DNA-damage, and is therefore key in regulating a vast
array of proteins involved in cell cycle progression and
check-points, DNA repair and apoptosis [1].
In the absence of cellular stress, p53 is maintained at
low levels by its ubiquitination and subsequent protea-
somal degradation. This process can be mediated by one
of several E3 ubiquitin ligases [2], but principally
by MDM2 (mouse double minute 2), as illustrated in
Figure 1A.
Conversely, in the presence of cellular stress stimuli,
two protein kinases - ATM (ataxia-telangiectasia
mutated) and ATR (ATM and Rad3-related) orchestrate
the DDR in order to preserve genome integrity. Whilst
ATM is mainly activated in response to double-strand
DNA breaks (DSBs), ATR is primarily activated follow-
ing replicative errors that result in single-stranded DNA,
however recent findings indicate DSB-mediated activa-
tion of ATM can also trigger activation of ATR [3,4].
Activation of ATM leads to phosphorylation and acti-
vation of CHK2, along with various other substrates,
resulting in the subsequent phosphorylation of both p53
and its negative regulator MDM2 (Figure 1B). Phos-
phorylation of MDM2 in close proximity to its RING
domain inhibits its ability to ubiquitinate p53, instead
promoting self-ubiquitination and degradation by the
proteasome.
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stabilisation and activation [5-7], bringing about its
translocation to the nucleus, where it has been shown to
bind preferentially to promoters which favour transcrip-
tion of genes that encode proteins required in stress-
induced cell cycle check-point control, DNA repair and
apoptosis. Adding to the complexity of p53-mediated
DDR signalling are several reports indicating that co-
operation of p53 with other transcription factors such as
hnRNP K and Miz-1 is necessary for the efficient tran-
scription of some p53 target genes, particularly those
encoding apoptogenic proteins [8-10].
The functional roles of p53 phosphorylation vary and
are yet to be fully elucidated. Evidence suggests that
phosphorylation of p53 at Ser20 leads to inhibition of
the p53/MDM2 interaction, preventing ubiquitin-
mediated p53 degradation and thereby enhancing p53
stabilisation [11-13]. On the other hand, phosphoryla-
tion of p53 at Ser46 has been shown to mediate the
selectivity of p53 in favour of promoters which enhance
apoptotic signalling, such as the p53-regulated apopto-
sis-inducing protein 1 (p53AIP) [14]. Furthermore, cer-
tain phosphorylations provide a means of negatively
regulating p53, as evidenced by observations that phos-
phorylation of p53 at Thr55 inhibits its nuclear localisa-
tion [15] and mediates its degradation [16], whilst
dephosphorylation of nucl e a rp 5 3a tS e r 2 7 6h a sb e e n
observed to occur as an early response to ionising radia-
tion [17].
There also exists much debate as to whether specific
phosphorylations are prerequisite for the stabilisation
and functional activity of p53. Findings in U2OS osteo-
blast cells show that isopropyl-ß-D-thiogalactoside-
induced (IPTG) sequestration of MDM2 by p14/ARF
led to phosphorylation of only a single p53 residue;
Ser392, whilst adriamycin caused phosphorylation of all
6 key serine residues (Ser6, 10, 15, 20, 37 and 392), but
no differences were observed between the activity of p53
in adriamycin versus IPTG-treated cells, seemingly indi-
cating that phosphorylation is not necessary for p53
activity [18]. However, Chehab et al observed complete
ablation of p53 stabilisation in response to UV treat-
ment or irradiation in cells where Ser20 was substituted
for alanine or aspartate [11].
Given the vast array of proteins under the regulation
of p53, and the fact that mutations to p53 are present in
over 50% of all human malignancies [19,20], there is
much interest in developing pharmacological agents
directed at p53-mediated responses. Recently, a novel
small molecule MDM2 antagonist has been developed;
Nutlin-3 (Figure 1C) interacts with the p53 binding
domain of MDM2, preventing negative regulation of
p53 by MDM2, hence allowing continuation of p53-
mediated signalling [21]. Studies by the same group also
showed that Nutlin-3 treatment of p53-positive HCT116
and RKO cells enhanced transcription of p53-responsive
genes including p21, MIC1 and MDM2, leading to the
initiation of apoptosis, despite the fact that no phos-
phorylation of p53 was observed at a number of key ser-
ine residues (Ser6, 15, 20, 37, 46 and 392) [22]. The
authors attribute their findings to the proposed non-
genotoxic action of Nutlin-3, however Nutlin-3-induced
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Figure 1 Schematic representation of the interactions between p53 and MDM2. (A) In the absence of stress signals, p53 is bound to its
negative regulator MDM2. MDM2 ubiquitinates p53, targeting it for degradation by the 26 S proteasome. (B) Cellular stress signals, such as that
bought about by DNA-damage lead to activation of ATM/ATR. ATM/ATR mediate the phosphorylation of MDM2 and p53. Phosphorylated MDM2
undergoes auto-ubiquitination and degradation by the 26 S proteasome. Phosphorylated p53 undergoes nuclear localisation, tetramerisation,
and binds to p53-responsive promoters to induce transcription of genes involved in the DDR. (C) Chemical structure of Nutlin-3.
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Page 2 of 11phosphorylation of p53 at Ser15 has since been reported
in both B-cell chronic lymphocytic leukaemia (B-CLL)
and mantle cell lymphoma (MCL) models [23].
I nt h ec u r r e n ts t u d yw ea s s e s s e dt h es t a b i l i s a t i o na n d
activation of p53 in HCT116
p53+/+ cells in response to
Nutlin-3, finding significant phosphorylation of Ser15,
along with Ser20 and Ser37. Furthermore, on investiga-
tion of other components of the DDR pathway, we show
Nutlin-3-mediated activation of ATM, CHK2, BRCA1
and H2AX, as well as upregulation of MDM2 and p21.
Nutlin-3 led to G1/S arrest in HCT116
p53+/+ cells, in
keeping with the established role of p53 in instigating
and maintaining G1 arrest, however in HCT116
p53-/-
cells, G2/M arrest was noted in response to Nutlin-3
treatment, demonstrating the ability of Nutlin-3 to
induce cell cycle checkpoint controls in a p53-indepen-
dent fashion. Additionally, in response to Nutlin-3, we
show nuclear H2AX foci formation, an early event in
the DDR caused by clustering of phosphorylated H2AX
moieties (gH 2 A X )a tt h es i t eo fD S B s .M o r e o v e r ,t h i s
phenomenon was also observed in HCT116 cells lacking
p53 (HCT116
p53-/-) and also in MDM2 deficient cells
(MEF
MDM2-/-), suggesting firstly that p53 status is dis-
pensable in the Nutlin-3-induced DDR, and secondly,
that the ability of Nutlin-3 to induce DNA-damage or
initiate the DDR is not connected to its role as an
MDM2 antagonist. These results suggest a secondary
role for Nutlin-3 as a DNA-damaging agent, contrary to
its proposed mechanism of action as a non-genotoxic
antagonist of MDM2. These data have implications for
the use of Nutlin-3, and for the future development of
pharmacological MDM2 antagonists for the treatment
of cancer.
Methods
Unless otherwise stated all antibodies were purchased
from New England Biolabs, Hertfordshire, UK, and all
reagents, including Nutlin-3, were purchased from
Sigma-Aldrich, Dorset, UK.
Cell Lines
Human colorectal cancer cell lines (HCT116
p53-/- and
HCT116
p53+/+) were obtained from Professor Galina
Selivanova (Karolinska Institute, Stockholm, Sweden),
and mouse embryonic fibroblast (MEF) cells deficient in
MDM2 (MEF
MDM2-/-)w e r eo b t a i n e df r o mP r o f e s s o r
Guillermina Lozano (MD Anderson Cancer Centre, Uni-
versity of Texas, USA). All cells were genotyped before
arrival using where necessary primers specific to the
deleted alleles. Cell lines were authenticated upon
receipt using immunoblotting. Cells were sustained in
Dulbecco’s Modified Eagle’s Medium, supplemented
with 10% fetal bovine serum, 1% Penicillin/Streptomy-
cin/L-Glutamine and 1% Amphotericin B (Invitrogen,
Renfrewshire, UK). Cells were incubated at 37°C in a
humidified atmosphere containing 5% CO2. Cells were
passaged twice weekly, and were seeded at 1 × 10
5cells/
mL during all experiments.
Western Blotting
Following varying length treatments with 10 μM Nutlin-
3 or 100 μM Etoposide, cells were collected and lysed in
2X laemmli lysis buffer (4% w/v SDS, 20% v/v glycerol,
120 mM tris pH6.8). A 5 μL volume of each sample was
diluted in 95 μLd H 20, and added to 1 mL Lowry solu-
tion (50 parts 2% w/v sodium carbonate, 0.1 M sodium
hydroxide solution, to 1 part 0.5% w/v copper(II)sul-
phate, 1% w/v sodium citrate solution), incubated at
room temperature for 10 minutes, added to 100 μL1M
folinciocalteau solution, and incubated for 30 minutes at
room temperature before being transferred to cuvettes
for determination of protein concentration using a Cam-
Spec-M330 spectrometer. Samples of equal protein con-
centration were then loaded onto 6-15% acrylamide gels
and underwent electrophoresis, followed by transfer
onto PVDF (polyvinylidene fluoride) membranes. Mem-
branes were blocked with 5% milk/TBS-T solution (5%
w/v Marvel milk powder in 1X TBS-T solution compris-
ing 50 mM Tris, 150 Mm sodium chloride, 0.364% v/v
hydrochloric acid, 0.5% v/v Tween-20) and probed over-
night at 4°C for specific proteins of interest. Standard
primary antibody dilutions were 1:1000 in 5% milk/TBS-
T solution, except for CHK2 (1:100 in 5% BSA/TBS-T
solution), tubulin and actin (Merck Chemicals, Nottin-
ghamshire, UK), used at 1:17000 in 5% milk/TBS-T
solution. Standard secondary antibody dilutions were
1:2000 prepared in 5% milk/TBS-T solution. Chemilu-
minescence was detected using Lumiglo reagent (New
England Biolabs, Hertfordshire, UK) according to manu-
facturer’s instructions, and hyperfilms (GE Healthcare,
Buckinghamshire, UK) were developed using an Amer-
sham SRX100A Hyperprocessor.
Flow Cytometry
After treatment with 100 μM Etoposide or 10 μM
Nutlin-3 for various time periods, cells were trypsinised
using 0.05% EDTA-free trypsin (Invitrogen, Renfrew-
shire, UK), collected and centrifuged, and the pellets
resuspended in 70% ethanol before being stored for 24
hours at -20°C. Cells were later centrifuged, washed
with 1X PBS and resuspended in 50 μg/mL Propidium
Iodide/Rnase A solution before cell cycle distribution
was assessed on a Beckman Coulter Cytomics FC500
flow cytometer.
Immunofluorescence
Cells in 6-well plates were treated with 100 μME t o p o -
side or 10 μM Nutlin-3 for varying time periods before
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meabilised with 0.5% v/v Triton-X100 solution, washed
in 1X PBS and incubated overnight at 4°C with various
antibodies prepared in 5% milk/TBS-T solution. Cells
were then washed with 1X PBS, incubated for 2 hours
with a 1:250 dilution of goat anti-rabbit Dylight488 anti-
body (New England Biolabs, Hertfordshire, UK) prepared
in 1X PBS, before being washed once again with 1X PBS.
Wells were then treated with one drop of Vectashield
mounting media containing DAPI (Vector Laboratories,
Cambridgeshire, UK), covered with glass coverslips and
sealed with clear nail polish. Cells were then observed at
40× magnification using a Zeiss LSM500 confocal micro-
scope and analysed using LSM Image Browser software
(Carl Zeiss, Oberkochen, Germany).
Results
Nutlin-3 induces stabilisation of p53 and activation of
p53 target proteins
In order to compare the efficiency of Nutlin-3-dependent
p53 stabilisation with that of known DNA-damaging
agents, we treated human colorectal cancer cells
(HCT116
p53+/+) with Etoposide (100 μM) or Nutlin-3 (10
μM). Treatment of HCT116
p53+/+ cells with these differ-
ent agents led to stabilisation of p53 from 2 hours. Stabi-
lisation of p53 was still apparent after 16 hours in cells
treated with either Etoposide or Nutlin-3 (Figure 2A). As
expected, no p53 was observed in HCT116
p53 -/- cells
treated with any of the two reagents throughout the time
course examined (Figure 2C).
Given that we observed stabilisation of p53 in
response to Nutlin-3, we sought to identify whether
Nutlin-3 caused activation of p53 target proteins;
MDM2 and p21. Indeed, following 4, 8 or 16 hour treat-
ments with Nutlin-3, activation of p21 was observed to
be similar to that induced by Etoposide. Additionally,
Nutlin-3-induced activation of MDM2 greatly exceeded
that resulting from Etoposide treatment throughout the
time course studied (Figure 2B).
Nutlin-3 induces phosphorylation of p53 at key serine
residues and activates several important DDR mediators
Following the observed stabilisation of p53 in
HCT116
p53+/+ cells induced by treatment with Etoposide
or Nutlin-3, we next sought to investigate whether or
not the observed Nutlin-3-dependent stabilisation of
p53 was a result of Nutlin-3-induced p53 phosphoryla-
tion. Therefore, the phosphorylation status of various
key serine residues known to be phosphorylated follow-
ing DNA-damage was examined in response to the
same two reagents over a 24 hours time-course. Indeed,
phosphorylation of Ser15, 20 and 37 was observed at
both 2 and 6 hour time points in response to Etoposide
and Nutlin-3 treatment (Figure 3A). However a marked
decrease in p53 phosphorylation was observed following
Nutlin-3 treatment at 24 hour point (Additional file 1).
Since it is well established that Etoposide-dependent
phosphorylation of p53 is a response to DNA-damage
generated by this agent, we went on to investigate
whether the unexpected Nutlin-3-induced p53 phos-
phorylation was due to a Nutlin-3-mediated DDR.
Therefore, we assessed the affect of Nutlin-3 on the
activation of CHK2 and ATM which are required for
DNA-damage-dependent phosphorylation and activation
Eto
Nut
unt Time (hours)
p53
p53
Actin
24 81 6
Actin
Time (hours) 48  1 6 unt
Eto
Nut
MDM2
Actin
p21
MDM2
Actin
p21
B A
Figure 2 Nutlin-3 induces stabilisation and phosphorylation of p53, and activates key p53 target proteins. (A) HCT116
p53+/+ cells were
untreated (treated with DMSO only) (unt) or treated with 100 μM Etoposide (Eto), or 10 μM Nutlin-3 (Nut) for the times indicated before
immunoblotting was used to analyze p53 stabilisation. Actin levels were used to assess equal loading. (B) HCT116
p53+/+ cells were treated with
100 μM Etoposide (Eto) or 10 μM Nutlin-3 (Nut) for the times indicated before immunoblotting was used to analyse MDM2 and p21 activation.
Actin levels were used to assess equal loading. (C) HCT116
p53-/- cells were untreated (treated with DMSO only) (unt) or treated 10 μM Nutlin-3
(Nut) for the times indicated before immunoblotting was used to analyze p53 stabilisation. Actin levels were used to assess equal loading.
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were observed in HCT116
p53+/+ cells following 1 hour
treatments with either Etoposide or Nutlin-3, as was
phosphorylation of BRCA1, an ATM target protein
required for the ATM-dependent DDR (Figure 3B).
Furthermore, in HCT116
p53-/- cells, phosphorylation of
both ATM and its target protein BRCA1 was also noted
following a 1 hour treatment with both Nutlin-3 and
Etoposide (Figure 3C).
Nutlin-3 induces G1/S cell cycle arrest
Given our findings that Nutlin-3 treatment induced p53
stabilisation and phosphorylation, as well as the activa-
tion of key DDR proteins and p53 target proteins
known to be involved in cell cycle control, we went on
to assess whether Nutlin-3 was capable of inducing cell
cycle checkpoints. Following treatment with either
Nutlin-3 or Etoptoside, HCT116
p53+/+ and
p53-/- cells
were analysed by flow cytometry. While HCT116
p53+/+
treatment with Nutlin-3 led to G1/S arrest, treatment
with Etoposide led to G2/M arrest (Figure 4A, Addi-
tional file 2 and Table 1). In contrast HCT116 p53-/-
cells were observed to arrest in G2/M in response to
both Nutlin-3 and Etoposide (Figure 4A, Additional file
2 and Table 2). Furthermore and in contrast to
HCT116
p53+/+, an increase in subG1 cell population was
observed in HCT116
p53-/-following Nutlin-3 treatment
(Figure 4A, Additional file 2 and Tables 1 and 2).
Nutlin-3 induces H2AX phosphorylation and foci
formation
One of the first proteins phosphorylated and activated
in response to DNA-damage is the histone variant,
H2AX [24]. Hence, we sought to investigate whether the
observed Nutlin-3-dependent activation of ATM and
CHK2 was due to a Nutlin-3-mediated DDR. Therefore,
HCT116
p53+/+ cells were treated with either Etoposide
or Nutlin-3, and H2AX phosphorylation was checked
Time (hours)  unt
  Eto
Ser15
Ser20
Ser37
Actin
Actin
Actin
 2 6 2 6
  Nut
p.ATM (Ser1981)
p.BRCA1 (Ser1524)
p.CHK2 (Thr68)
Actin
Time (hours) 1  unt 1  unt
 Eto  Nut
p.ATM (Ser1981)
A B
C
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Time (hours) 1  unt 1  unt
 Nut  Eto
p.BRCA1 (Ser1524)
Figure 3 Nutlin-3 leads to phosphorylation of several important DDR mediators. (A) HCT116
p53+/+ cells were untreated (treated with
DMSO only) (unt) or treated with 100 μM Etoposide (Eto) or 10 μM Nutlin-3 (Nut) for the times indicated before immunoblotting was used to
analyse phosphorylation of p53 at Ser15, Ser20 and Ser37. Actin levels were used to assess equal loading. (B) HCT116
p53+/+ cells were untreated
(treated with DMSO only) (unt) or treated with 10 μM Nutlin-3 (Nut) or 100 μM of Etoposide (Eto) for 1 hour before the phosphorylation of ATM
(Ser1981), BRCA1 (Ser1542) and CHK2 (Thr68) were analysed using immunoblotting. Actin levels were used to assess equal loading. (C)
HCT116
p53-/- cells were untreated (treated with DMSO only) (unt) or treated with 10 μM Nutlin-3 or 100 μM of Etoposide (Eto) for 1 hour before
the phosphorylation of ATM (Ser1981) and BRCA1 (Ser1542) were analysed using immunoblotting. Actin levels were used to assess equal
loading.
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Page 5 of 11both 1 and 4 hours following treatment. Indeed, H2AX
phosphorylation was induced in response to both Etopo-
side and Nutlin-3 treatment (Figure 5A).
We next sought to establish whether the observed
Nutlin-3-induced activation of H2AX phosphorylation
was indicative of gH2AX foci formation, an event recog-
nised to occur early on in the DDR [24]. Indeed, treat-
ment of HCT116
p53+/+ cells with Etoposide or Nutlin-3
was observed to induce gH2AX foci formation from as
early as 30 minutes following treatment. Foci formation
was most notable in response to Etoposide treatment,
but was nevertheless clearly visible in response to treat-
ment with Nutlin-3 (Figure 5B).
Nutlin-3 induced responses are independent of p53 and
Nutlin-3- mediated inhibition of MDM2
We next sought to clarify the effect of p53 status on the
ability of Nutlin-3 to induce the DDR. We therefore
treated HCT116
p53-/- cells with Etoposide or Nutlin-3
and assessed the phosphorylation of gH2AX. Here,
increases in gH2AX phosphorylation were observed in
HCT116
p53-/- cells treated with either Etoposide or
Nutlin-3 (Figure 6A). Furthermore, formation of gH2AX
foci were clearly visible in HCT116
p53-/- cells following
30 minutes treatment with Etoposide, an effect which
was comparable in cells treated with Nutlin-3 for the
same time period (Figure 6B).
Having established that Nutlin-3 was capable of indu-
cing DDR independent of p53 status, we went on to
assess whether the ability of Nutlin-3 to induce DDR
was dependent on its ability to inhibit MDM2. Here we
assessed the effect of Nutlin-3 on formation of gH2AX
foci in mouse embryonic fibroblasts deficient in MDM2
(MEF
MDM2-/-). We observed clear formation of gH2AX
foci after 30 minutes Nutlin-3 treatment, similar to that
induced in cells treated with Etoposide for the same
length of time (Figure 6C). Furthermore, in MEF
MDM2-/-
cells, phosphorylation of ATM, ChK2, BRCA1 and
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Figure 4 Nutlin-3 induces p53-independent cell cycle checkpoint controls. HCT116
p53+/+ and HCT116
p53-/- cells were treated with either 0,
10, 15 or 20 μM Nutlin-3 (Nut) or 100 μM of Etoposide (Eto). After 18 hours, cell cycle distribution was assessed using flow cytometry. (A) Chart
showing percentage of HCT116
p53+/+ cells in either G1 or G2 cell cycle population following either Nutlin-3 or etoposide treatment as described
above. (B) Chart showing percentage of HCT116
p53-/- cells in both G1 and G2 cell cycle population following either Nutlin-3 or Etoposide
treatment as described above.
Table 1 Representative percentages of HCT11 p53
+/+ cells
in the different cell cycle phases following Nutlin-3 or
Etoposide treatment as described in Additional file 2
p53+/+ subG1 G1 S G2/M
Control 4.8 46.8 16.2 32.2
Nut 10 nM 3.1 59.1 11.9 25.9
Nut 15 nM 3.1 63.7 7.9 25.3
Nut 20 nM 3.1 66.0 5.9 25.0
Etoposide 20.9 17.1 12.0 50.0
Table 2 Representative percentages of HCT11 p53
-/- cells
in the different cell cycle phases following Nutlin-3 or
Etoposide treatment as described in Additional file 2
p53-/- subG1 G1 S G2/M
Control 3.2 56.3 14.8 25.7
Nut 10 nM 5.7 19.5 25.3 49.5
Nut 15 nM 7.7 18.6 22.7 51.0
Nut 20 nM 7.2 18.3 22.7 51.8
Etoposide 10.2 13.7 19.1 57.0
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Nutlin-3, and markedly decreased by 24 hours (Addi-
tional file 3).
Discussion
Numerous serine and threonine residues (mainly those
located in the N-terminal part of the0020p53 protein)
are targets for phosphorylation in response to a diverse
range of stress factors. Following DNA-damage for
instance, various protein kinases including ATM and
CHK2 are activated and lead to p53 phosphorylation,
subsequently resulting in stabilisation and activation of
p53 [5-7].
The requirement of these phosphorylation events for
the stabilisation and activation of p53 remains a some-
what controversial topic, as do the consequences of
controlling the p53 pathway using the relatively newly
developed MDM2 antagonists such as Nutlin-3.
For example, there is debate as to whether MDM2
antagonism may affect p53 protein modifications or
functions. A study carried out by Thompson et al using
Nutlin-3, showed that phosphorylation of p53 on key
Control Etoposide Nutlin-3
HCT116 p53+/+
p.H2AX (Ser139)
Actin
  unt Time (hours)
Actin
p.H2AX (Ser139)
Eto
Nut
  1  4
A
B
Figure 5 Nutlin-3 induces H2AX phosphorylation and gH2AX foci in HCT116
p53+/+ cells. (A) HCT116
p53+/+ cells were left untreated (unt) or
treated with 100 μM Etoposide (Eto), 10 μM Nutlin-3 or (Nut) for 1 or 4 hours before the phosphorylation of H2AX (Ser139) was assessed using
immunoblotting. Actin levels were used to assess equal loading. (B) Representative confocal microscopy images of gH2AX foci formation in
HCT116
p53+/+ cells treated with either 100 μM Etoposide or 10 μM Nutlin-3 for 30 minutes.
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stabilisation and activation. Indeed, whilst Thompson
et al still observed stabilisation and activation of p53,
no phosphorylation was detected following Nutlin-3
treatment [22].
In stark contrast, Drakos et al have since shown
Nutlin-3-dependent induction of p53 phosphorylation at
Ser15 in SP-53, Z-138, M-1 and Granta-519 MCL cell
lines [23]. Nutlin-3-dependent p53 phosphorylation at
Ser15 has also been observed in normal CD19
+ B-cells,
peripheral blood mononuclear cells (PBMCs), bone mar-
row mononuclear cells (BMMCs) and B-CLL cells to a
level similar to that noted in response to fludarabine
treatment, and in excess of that resulting from treat-
ment with the protease inhibitor clasto-latacystin [25].
Indeed in the current study, we observed Nutlin-3-
induced stabilisation and activation of p53 at levels
comparable with that induced by the genotoxic DNA
topoisomerase II inhibitor; Etoposide (Figure 2A and
2B). We also detected Nutlin-3-induced phosphorylation
of p53 at Ser15, as well as at two other key serine resi-
dues; Ser20 and Ser37 (Figure 3A), indicating that
Nutlin-3 does not only disrupt the interaction between
MDM2 and p53, but could also play a role in activating
DDR pathways resulting in p53 phosphorylation, and
subsequent activation of downstream target proteins
involved in for example, cell cycle checkpoint control.
Our results are in sharp contrast to the previous obser-
vations of Thompson et al [22]. In the current study, we
checked p53 phosphorylation at earlier time points
following Nutlin-3 treatment (as early as 2 hours, see
Figure 2), however data in the Thompson et al study
were obtained after 24 hour treatments with Nutlin-3,
which could explain why such a difference is seen
between the two studies. Indeed we also observed a
marked decrease in these phosphorylations at 24 hours
in response to Nutlin-3 (Additional file 1).
Since the activation of ATM and its downstream sub-
strate CHK2 are well established as being responsible for
DNA-damage-dependent p53 phosphorylation [5-7], we
went on to investigate whether the observed Nutlin-3-
dependent p53 phosphorylation was as a result of activa-
tion of these two kinases. Indeed, to our knowledge, we
show for the first time that Nutlin-3 treatment triggers
phosphorylation of ATM (Ser1981) and CHK2 (Thr68) in
HCT116
p53+/+ cells (Figure 3B), demonstrating that
Nutlin-3-mediated p53 phosphorylation is due to Nutlin-3
behaving as an activator of ATM and CHK2. Indeed our
p.H2AX (Ser139)
Actin
  unt             1                 1
Time (hours)
Eto              Nut
Control Etoposide Nutlin-3
HCT116 p53-/-
Control Etoposide Nutlin-3
MEF MDM2-/-
A B
C
Figure 6 Nutlin-3 induces H2AX phosphorylation and _H2AX foci formation independent of both p53 and MDM2 status.
(A) HCT116
p53-/- cells were left untreated (unt) or treated with 100 μM Etoposide (Eto) or 10 μM Nutlin-3 (Nut) for 1 hour before the
phosphorylation of H2AX (Ser139) was assessed using immunoblotting. Actin levels were used to assess equal loading. (B) Representative
confocal microscopy images of gH2AX foci formation in HCT116
p53-/- cells treated with either 100 μM Etoposide or 10 μM Nutlin-3 for 30
minutes. (C) Representative confocal microscopy images of gH2AX foci formation in MEF
MDM2-/- cells treated with either 100 μM Etoposide or
10 μM Nutlin-3 for 30 minutes.
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Page 8 of 11observation that Nutlin-3 also led to phosphorylation of a
well established ATM target; BRCA1 (Ser1524) further
supports a role for Nutlin-3 as an activator of the ATM
kinase. Moreover, the phosphorylation of ATM and its
target protein BRCA1 in HCT116
p53-/- cells (Figure 3C)
suggests that the Nutlin-3-mediated activation of ATM
and the subsequent phosphorylation of BRCA1 are
triggered independently of p53.
Following DNA-damage, it is known that cells activate
checkpoints to temporarily halt the cell cycle [26],
allowing for DNA repair or destruction of the damaged
cell by apoptosis. The G1-S and intra-S-phase check-
points regulate transition into, and progression through
S phase in response to DNA-damage, while the G2-M
checkpoint regulates entry into mitosis [26]. Since ATM
and CHK2 are amongst the main activators of these
checkpoints in response to DNA-damage, we sought
to determine whether cell cycle checkpoints could be
triggered by Nutlin-3 treatment. Whilst Etoposide led
to clear G2/M arrest, Nutlin-3 treatment led to marked
G1/S arrest in HCT116
p53+/+ cells (Figure 4A), in keep-
ing with the established role of p53 in triggering and
maintaining G1/S arrest [27].
Conversely, in HCT116
p53-/- cells, Nutlin-3 led to G2/
M arrest (Figure 4B), demonstrating Nutlin-3-mediated
p53-independent induction of the G2/M cell cycle
checkpoint, similar to that observed following Etoposide
treatment. In addition, an increase in the sub-G1 cell
population was also observed. Since sub-G1 is indicative
of apoptotic cells, this suggests that Nutlin-3 may trigger
p53-independent apoptosis. Given the absence of func-
tional p53 in this instance, this prompted us to question
whether Nutlin-3 was inducing the DDR without
directly generating DNA-damage, or if the DDR was
being activated due to Nutlin-3-induced DNA-damage.
One widely established indicator of DNA damage is the
rapid phosphorylation of the histone variant H2AX at its
C-terminal serine residue (Ser139) to form gH2AX, acti-
vation of which leads to its recruitment and subsequent
accumulation (along with various repair proteins)
into foci at the site of DNA damage [24]. Here,
Nutlin-3 clearly induced the phosphorylation of H2AX
(Figure 5A), and in addition was observed using immuno-
fluorescent staining to cause clear gH2AX foci formation,
similar to that observed in Etoposide-treated cells (Figure
5B). These findings demonstrate that Nutlin-3-dependent
phosphorylation of p53 is due to the ability of Nutlin-3
to induce DNA-damage, or to otherwise activate path-
ways that are stimulated in response to DNA damage.
Recently, Verma et al have observed phosphorylation
of H2AX in HCT116
p53+/+ following Nutlin-3 treatment.
Nevertheless, an absence of gH2AX staining was noted
by Verma et al unless Nutlin-3 was combined with
treatment with the DNA damage inducer Hydroxyurea,
and no phosphorylation of Ser15 was seen [28]. It is
noteworthy that Verma et al observed these effects fol-
lowing a 24 hour treatment with Nutlin-3, whilst in the
current study earlier time points were used after consid-
e r i n gp r e v i o u sf i n d i n g si n d i c a t i n gt h a tH 2 A Xf o c if o r -
mation occurs as early as 1 minute after DNA-damage
and peak at around 30-60 minutes [29-31], and previous
observations that DNA-damage-induced stabilization
and phosphorylation of p53 peak at 4-6 hours, declining
thereafter [32,33].
Verma and colleagues attribute the induction of gH2AX
staining to Nutlin-3-induced p53-mediated slowing of
non-homologous end joining events following formation
of DSBs during normal replicative processes, possibly as a
way to ensure the accuracy of the repair process. However,
in the current study we show Nutlin-3-induced phosphor-
ylation of H2AX and formation of gH2AX foci in
HCT116
p53-/- cells (Figure 6A and 6B). Coupled with the
G2/M arrest we observed in p53 negative HCT116 cells,
our data indicate that p53 is dispensable in the Nutlin-3-
induced DDR. Furthermore, our observation that Nutlin-3
induces formation of gH2AX foci as well as ATM, ChK2
and BRCA1 phosphorylation in cells devoid of MDM2
(Figure 6C and Additional file 3), suggests that the second-
ary ability of Nutlin-3 to induce DNA-damage is not
related to its primary function as an MDM2 antagonist.
Conclusions
Direct inhibition of MDM2 using Nutlin-3 clearly pro-
vides a means of activating p53, and restoring p53 sig-
naling, however in light of recent findings including
those presented in the current study, we suggest Nutlin-
3 is itself capable of instigating DNA-damage signaling.
To our knowledge, we show for the first time that
Nutlin-3 induces DDR activation in a p53-and MDM2-
independent fashion. Further investigation is required to
fully elucidate the effect of Nutlin-3 on p53-dependent
and-independent DDR mechanisms, as well as its effects
on the post-translational modification and functionality
of p53, understanding of which will undoubtedly facili-
tate the development of Nutlin-3 and other MDM2
antagonists as potential cancer therapies.
Additional material
Additional file 1: Nutlin-3 leads to phosphorylation of key p53
Serine residues associated with DNA-damage. HCT116
p53+/+ cells
were untreated (treated with DMSO only) (unt) or treated with 100 μM
Etoposide (Eto) or 10 μM Nutlin-3 (Nut) for the times indicated before
immunoblotting was used to analyse phosphorylation of p53 at Ser15,
Ser20 and Ser37. Actin levels were used to assess equal loading.
Additional file 2: Nutlin-3 induces p53-independent cell cycle
checkpoint controls. Representative histograms of HCT116
p53+/+ and
HCT116
p53-/- cells following Nutlin-3 or Etoposide treatment. HCT116
p53
+/+ and HCT116
p53-/- cells were treated with either 0, 10, 15 or 20 μM
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Page 9 of 11Nutlin-3 (Nut) or 100 μM of Etoposide (Eto). After 18 hours, cell cycle
distribution was assessed using flow cytometry.
Additional file 3: Nutlin-3 leads to phosphorylation of several
important DDR mediators, and results in phosphorylation of H2AX
in MDM2 minus cells. MEF
MDM2-/- cells were untreated (treated with
DMSO only) (unt) or treated with 10 μM Nutlin-3 (Nut) or 100 μMo f
Etoposide (Eto) for 1 or 24 hours before the phosphorylation of ATM
(Ser1981), BRCA1 (Ser1542), CHK2 (Thr68) and H2AX (Ser139) were
analysed using immunoblotting. Actin levels were used to assess equal
loading.
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